What is RadMD?
RadMD operates as a high-authority expertise-based image management service organization. The company provides critical consulting, rigorous training, and independent imaging services tailored for pharmaceutical, biotechnology, and medical device enterprises. By designing sophisticated imaging endpoints and conducting comprehensive image reviews for over 600 clinical studies, RadMD has solidified its reputation as a leader in the field. Their operational model, which includes training over 1,000 clinical sites, ensures that image assessment protocols are optimized for accuracy and regulatory compliance, serving as a vital link in the drug development and medical device approval pipeline.
How much funding has RadMD raised?
RadMD has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in RadMD
PPP
Public-Private Partnership
What's next for RadMD?
Following this late-stage financing, RadMD is poised to scale its service offerings and enhance its technological infrastructure. The strategic allocation of these funds will likely focus on expanding the company's pool of independent readers and refining its proprietary image analysis methodologies. As the demand for high-fidelity imaging data in clinical trials continues to rise, RadMD is strategically positioned to capture additional market share. The company's focus will remain on maintaining its rigorous standards for imaging endpoints while potentially exploring new therapeutic areas that require complex, data-driven image assessment. This growth phase is expected to solidify RadMD's role as an indispensable partner for global life sciences firms navigating the complexities of modern clinical research.
See full RadMD company page
